Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine

Clinical Pharmacokinetics

Volumn 37, Issue 2, 1999, Pages 105-125

  White, Nicholas J ^a,b,c   Van Vugt, Michele ^a,b,d   Ezzet, Farkad ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL; DIHYDROARTEMISININ; PLASMA PROTEIN;

ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSFORMATION; FOOD INTAKE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA; MALARIA FALCIPARUM; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0032862673     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199937020-00002     Document Type: Review

References (58)

1. Jiao XQ, Liu GY, Shan CQ, et al. Phase II trial in China of a new and rapidly-acting and effective antimalarial CGP 56697, for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health 1997; 28: 476-81
2. von Seidlein L, Jaffar S, Pinder M, et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis 1997; 176: 1113-6
3. van Vugt M, Brockman A, Gemperli B, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 1998; 42: 135-9
4. Hatz C, Abdulla S, Mull R, et al. Efficacy and safety of CGP 56697 (artemether and benflumetol) compared wilh chloroquint to treat acute falciparum malaria in Tanzanian children aged 1-5 years. Trap Med Int Health 1998; 3: 495-504
5. Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83
6. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603-8
7. Price RN, Nosten F, Luxemburger C, et al. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trap Med Hyg 1995; 89: 523-7
8. Wernsdorfer WH, Landgraf B, Kilimali VAEB, et al. Activity of benflumetol and its enantiomers in fresh isolates of Plasmodium falciparum from East Africa. Acta Tropica 1998; 70: 9-15
9. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87: 75-8
10. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemothor 1997; 41: 1413-22
11. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1998; 1: 3-9
12. Atkinson JD, Ward SA. The use of independently acting drug combinations to reduce the rate of resistance acquisition in Plasmodium falciparum malaria: studies with lumefantrine, artemether, and co-artemether [abstract]. European Congress on Tropical Medicine; 1998 Sep 14-18; Liverpool
13. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response or CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46: 553-62
14. Looareesuwan S, Wilairatana P, Chokejindachai W, et al. A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment or acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999; 60: 238-43
15. van Vugt M, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine in the treatment of multi drug resistant falciparum malaria. Am J Trop Med Hyg. In press
16. Shmuklarsky MJ, Klayman DL, Milhous WK, et al. Comparison of beta-artemether and beta-arteether against malaria parasites in vitro and in vivo. Am J Trop Med Hyg 1993; 48: 377-84
17. Basco LK, Le Bras J. In vitro activity or artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am Journal Trop Med Hyg 1993; 49: 301-7
18. Teja-Isavadharm P, Nosten F, Kyle DE, et al. Comparative bio-availability of oral, rectal and intramuscular artemether in healthy subjects - use of simultaneous measurement by high performance liquid chromatography with electrochemical detection and bioassay. Br J Clin Pharmacol 1996; 42: 599-604
19. ter Kuile F, White NJ, Holloway P, et al. Plasmodium falciparum: in-vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76: 86-95
20. Pradines B, Tall A, Fusai T, et al. In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother 1999; 43: 418-20
21. Basco LK, Bickii J, Ringwald P. In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundc, Cameroon. Antimicrob Agents Chemother 1998; 42: 2347-51
22. Kamchonwongpaisan S, Meshnick SR. The mode of action of the antimalarial artemisinin and its derivatives. Gen Pharmacol 1996; 27: 587-92
23. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88 Suppl. 1: 41-3
24. Melendez V, Peggins JO, Brewer TG, et al. Determination or the antimalarial arteether and its dethylated metabolite dihydroartemisinin in plasma by high performance liquid chromatography with reductive electrochemical detection. J Pharm Sci 1991; 80: 132-8
25. Navaratnam V, Mansor SM, Chin LK, et al. Determination of artemether and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. J Chromatogr (B) Biomed Appl 1995; 669: 289-94
26. Edwards G. Measurement of artemisinin and its derivatives in biological fluids. Trans R Soc Trop Med Hyg 1994; 88 Suppl. I: 37-9
27. Zeng MY, Lu ZL, Yang SC, et al. Determination of benflumctol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1996; 681: 299-306
28. Mansor SM, Navaratnam V, Yahaya N, et al. Determination of a new antimalarial drug, benflurnectol, in blood plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996; 682: 321-5
29. van Vugt M, Ezzet F, Phaipun L, et al. The relationship between capillary and venous concentrations of lumefantrine (benflumetol). Trans R Soc Trop Med Hyg 1998; 92: 564-5
30. Grace JM, Aguilar AJ, Trotman KM, et al. Metabolism of β-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P-450. Drug Metab Dispos 1998; 26: 313-17
31. van Agtmael MA, Van Der Graaf CA, Dien TK, et al. The contribution of the enzymes CYP2D6-and CYP2C19 in the demethylation of artemether in healthy subjects. Br J Pharmacol 1998; 125: 159-67
32. Leo KU, Grace JM, Li Q, et al. Effects of Plasmodium berghei infection on arteether metabolism and disposition. Pharmacology 1997; 54: 276-84
33. Batty KT, Hett KF, Edwards G, et al. Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisnin using rat liver perfusions and microsomes. Br J Pharmacol 1998; 125: 159-67
34. Murdoch RT, Ghabrial H, Mihaly GW, et al. Malaria infection impairs glucuronidation and biliary excretion by the isolated perfused rat liver. Xenobiotica 1991; 15: 71-82
35. van Agtmael MA, Gupta V, van Boxtel CJ. A glass of grapefruit juice makes new, malaria treatment more effective [abstract A-081]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA)
36. 14C-dihydroartemisinin to plasma proteins and red blood cells of human and animal species in-vivo and in-vitro [abstract PpA 144]. 21st Annual Meeting Experimental Biology; 1998; San Francisco
37. Lee IS, Hufford CD. Metabolism of antimalarial sesquiterpene lactones. Pharmacol Ther 1990; 48: 345-55
38. Chi HT, Ramu K, Baker JK, et al. Identification of the in-vivo metabolites of the antimalarial arteether by thermospray high performance liquid chromatography/mass spectrometry. Biol Mass Spectrum 1991; 20: 609-28
39. Novartis AG. Data on file
40. Na Bangchang K, Karbwang J, Thomas CG, et al. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J Clin Pharmacol 1994; 37: 249-53
41. Mordi MN, Mansor SM, Navaratnam V, et al. Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br J Clin Pharmacol 1998; 43: 363-5
42. Bindschedler M, Degen P, Lu ZL, et al. Comparative bioavailability of benflurnetol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects [abstract]. XIVth International Congress for Tropical Medicine and Malaria; 1996 Nov 17-22; Nagasaki
43. White NJ. Antimatarial pharmacokinetics. Br J Clin Pharmacol 1992; 34: 1-10
44. Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990; 46: 673-87
45. Davidian M, Giltinan AR. Nonlinear models for repeated measurements data. London: Chapman and Hall, 1995
46. Field JW. Blood examination and prognosis in acute falciparum malaria. Trans R Soc Trop Med Hyg 1949; 43: 33-48
47. Brewer TG, Peggins JO, Grate SJ, et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 1994; 88 Suppl. 1: 33-6
48. Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994; 51: 251-9
49. Price RN, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute uncomplicated falciparum malaria treated with artemisinin derivatives. Am J Trap Med Hyg 1999; 60: 547-55
50. Nosten I, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-6
51. c interval in African children treated for Falciparum malaria. Am J Trop Med Hyg 1998; 59: 503
52. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24: 474-90
53. Molyneux ME, Looareesuwan S, Menzies IS, et al. Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. Am J Trop Med Hyg 1989; 40: 470-76
54. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster, Lancet 1999; 353: 1965-7
55. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multi-drug resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170: 971-7
56. Milton KA, Edwards G, Ward SA, et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol 1989; 28: 71-7
57. Husscin Z, Eaves J, Hutchinson DB, et al. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997; 61: 518-30
58. Yorke W, Macfie JWS. Observations on malaria made during treatment of general paralysis. Trans R Soc Trap Med Hyg 1924; 18: 33